Vistagen Therapeutics Also Planning To Initiate A Palisade Phase 2 Re-dosing Trial In 2H Of 2024 - 8K
Portfolio Pulse from Benzinga Newsdesk
Vistagen Therapeutics is planning to initiate a Palisade Phase 2 re-dosing trial in the second half of 2024, according to an 8K filing.
October 02, 2023 | 11:21 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vistagen Therapeutics' announcement of a planned Palisade Phase 2 re-dosing trial in 2H 2024 could potentially impact the company's stock.
The announcement of a new clinical trial typically has a neutral to positive impact on a biotech company's stock. However, the impact on Vistagen's stock will depend on various factors, including the market's perception of the potential success of the trial, the company's current financial situation, and the overall market conditions.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100